Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.89 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.89 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.89 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.89 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.89 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.89 |
| ▸ | PFKP | Q01813 | 1/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.89 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.89 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.89 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vistusertib SCHEMBL22449928 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL1214881 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29397309 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29353400 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL20734874 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL290672 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29350053 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL23604916 | 0.90 | MTOR (0.82) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL23604917 | 0.90 | MTOR (0.82) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449835 | 0.90 | MTOR (0.90) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | NORTHWESTERN UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206700-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | MTOR 461/4885PIK3CA 1124/4885PIK3CD 2304/4885 |
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | ATG4B, ATG4A, ATG7 | MTOR 219/4885PIK3CA 883/4885PIK3CD 408/4885 |
| US-20160137634-A1 | Chemical Compounds | MKI67, CCNI, TP53 | MTOR 461/4885PIK3CA 1124/4885PIK3CD 2304/4885 |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | ATG4B, ATG4A, ATG7 | MTOR 219/4885PIK3CA 883/4885PIK3CD 408/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 11/4885PIK3CD 40/4885 |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 11/4885PIK3CD 40/4885 |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 9/4885PIK3CD 38/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4823/4885PIK3CA 2528/4885PIK3CD 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.